Ryght AI Partners with Global CRO Biorasi to Deliver AI-Powered Feasibility Solutions to Biotech and Biopharma Sponsors
Advanced AI Platform Enables More Accurate Site Selection and Faster Study Startup Across Key Therapeutic Areas
Partnership brings real-time site identification, feasibility, activation and automated trial optimization to Biorasi’s sponsor clients, reducing trial delays and improving cost effectiveness
LAGUNA BEACH, Calif., Aug. 15, 2025 /PRNewswire/ — Ryght AI, the clinical trials AI technology company transforming site activation and optimization through AI digital twins of every research site in the world, today announced a strategic partnership with Biorasi, a leading global clinical research organization (CRO) specializing in dermatology, oncology, neurology, and nephrology studies. This collaboration immediately enhances Biorasi’s service offering to biotech and biopharma sponsors with Ryght’s advanced AI-driven site selection and feasibility platform.
The partnership addresses critical industry challenges that cost sponsors millions annually: inaccurate site selection, prolonged feasibility timelines, unpredictable enrollment forecasting and suboptimal site performance. By integrating Ryght AI’s platform into Biorasi’s operations, sponsors gain access to granular, real-time insights on site performance and recruitment capacity – transforming site selection, feasibility and trial performance from guesswork into data-driven decision making.
